The review looked at eight clinical trials of various anti-malaria drugs -- including mefloquine, atovaquone-proguanil and the antibiotic doxycycline. All three are considered drugs of choice for travelers heading to most malaria-endemic regions. However, the study found, both atovaquone-proguanil -- sold under the brand-name Malarone -- and doxycycline appear to have fewer side effects.
With these two drugs, there is lower risk of nausea, stomach pain and other gastrointestinal side effects, and also neurological and psychiatric side effects, such as dizziness, sleep disturbances, anxiety and depression. There were no severe side effects -- problems that were life-threatening or required hospitalization -- in any of the studies.
Mefloquine, which is better difference between malarone and chloroquine for uses like: Malaria. If you miss a dose, take a dose as soon as you remember. Chloroquine is structurally related to quinine and quinidine, and cardiotoxicity resulting from any of those agents could be indistinguishable. While chloroquine enhanced infectivity of P. Malarone vs Doxycycline. Between difference chloroquine and malarone It is used to treat and prevent malaria, including chloroquine -resistant malaria.
Difference between Malaria and Dengue. Common side effects include abdominal pain, vomiting, diarrhea, cough, and itchiness In all, 1. There is no difference between difference between malarone and chloroquine the antimalarial agent hydroxychloroquine and placebo related to withdrawals due to adverse events rate.
Roskell, Jeffrey D. Concerns about the tolerability of mefloquine highlight the need for new drugs to prevent malaria. Atovaquone-proguanil Malarone; GlaxoSmithKline was safe and effective for prevention of falciparum malaria in lifelong residents of malaria-endemic countries, but experience in nonimmune people is limited. In a randomized, double-blind study, nonimmune travelers received malaria prophylaxis with atovaquone-proguanil subjects or mefloquine subjects.
Information about adverse events AEs and potential episodes of malaria was obtained 7, 28, and 60 days after travel. AEs were reported by an equivalent proportion of subjects who had received atovaquone-proguanil or mefloquine No confirmed diagnoses of malaria occurred in either group.
Atovaquone-proguanil was better tolerated than was mefloquine, and it was similarly effective for malaria prophylaxis in nonimmune travelers. Growing international travel and the continued spread of resistance to antimalarial drugs increase the risk of malaria for travelers.
As many as 30, travelers from industrialized countries develop malaria each year, with record numbers of imported cases of malaria reported in many North American and European countries [ 1 , 2 ]. Most cases of imported malaria are preventable, but many travelers fail to use or comply with appropriate chemoprophylaxis [ 3 ].
An important factor contributing to this failure is the concern about side effects associated with antimalarial chemoprophylaxis. Mefloquine is highly effective in preventing malaria, but articles in the medical and lay press that highlight the neuropsychiatric side effects of mefloquine have caused many travelers to use less-effective alternatives or to avoid chemoprophylaxis altogether [ 4—8 ]. Previous studies of lifelong residents of malariaendemic areas have shown that a fixed-dose combination of atovaquone and proguanil hydrochloride Malarone; GlaxoSmithKline is highly effective for prophylaxis of malaria caused by Plasmodium falciparum and has a safety profile similar to placebo [ 9—11 ].
In addition, both atovaquone and proguanil have causal prophylactic activity against the hepatic stages of P. We conducted a randomized, double-blind, controlled clinical trial to compare the safety and efficacy of atovaquone-proguanil with the safety and efficacy of mefloquine in nonimmune travelers. The prospectively defined hypothesis was that the frequency of adverse events AEs in subjects who were to receive atovaquone-proguanil would not be higher than the frequency of AEs in subjects who were to receive mefloquine.
Frequency of treatment-limiting AEs and efficacy of prophylaxis were secondary end points. In brief, nonimmune subjects who traveled to a malaria-endemic area for up to 28 days were evaluated 7, 28, and 60 days after return to obtain information about a targeted list of AEs and potential episodes of malaria.
Study drug dosing regimens. Without knowledge of treatment assignment, and after discussion with the subject, each investigator assessed whether there was a reasonable possibility that each AE was caused by the study drug. An AE was treatment emergent if it started while the subject was taking the study drug. Serum samples collected before and 4 weeks after travel were tested for antibodies to a malaria circumsporozoite protein [ 16 ] to define the minimum number of subjects exposed to malaria-infected mosquitoes and, in subjects with a potential diagnosis of malaria, for antibodies to blood-stage malaria parasites [ 17 ] to confirm or reject the diagnosis.
Compliance with study drug use was assessed at the 4-week follow-up visit by interviewing the subject, reviewing a diary card, and counting unused pills. Blood samples for routine tests of hematology hemoglobin level, WBC count, and platelet count and chemistry levels of creatinine and alanine aminotransferase were obtained before and 4 weeks after travel from all subjects at 1 site.
The primary study end point was the overall frequency of AEs, regardless of attributability to study drug, assessed 7 days after leaving the malaria-endemic area and analyzed in the intent-to-treat population of all subjects who were randomized and who received at least 1 dose of study drug. Secondary study end points were the frequency of treatment-limiting AEs and the efficacy of prophylaxis.
Because the P values are unadjusted and multiple comparisons will inflate the type I error, care should be taken when interpreting these comparisons. Atovaquone-proguanil or matching placebo was supplied as full-strength Malarone tablets GlaxoSmithKline , which contain mg of atovaquone and mg of proguanil hydrochloride, and Malarone Pediatric tablets GlaxoSmithKline , which contain Subjects were instructed to take atovaquone-proguanil active or placebo daily, starting 1—2 days before entering a malaria-endemic area and continuing until 1 week after leaving the malaria-endemic area.
Mefloquine mg tablets; Lariam; F. Hoffman La-Roche or matching placebo was administered according to standard recommendations of the World Health Organization [ 19 ]. Subjects were instructed to take mefloquine active or placebo weekly, starting at least 1 week and preferably 2—3 weeks before entering a malaria-endemic area, and continuing until 4 weeks after leaving the malaria-endemic area.
The 2 groups were well balanced with respect to baseline demographics, history of malaria, travel destination, and duration of travel table 1. Forty-two subjects 4. Baseline characteristics of the study groups in a comparison of atovaquone-proguanil with melfoquine for malaria prophylaxis.
All subjects and study personnel remained blinded to treatment assignment with 5 exceptions. Two subjects in the atovaquone-proguanil group and 3 in the mefloquine group lost their study drug during their return trip from a malaria-endemic area, and the investigator broke the blind to enable completion of postexposure prophylaxis with active drug.
The difference in frequency of AEs in the intent-to-treat population was 4. The total number of AEs reported was Because of the different recommended pretravel dosing regimens, subjects randomized to receive atovaquone-proguanil started receiving mefloquine placebo up to 3 weeks before starting atovaquone-proguanil.
There were also 3 subjects in the mefloquine group who started receiving atovaquone-proguanil placebo before starting active mefloquine. Excluding events that occurred while subjects were receiving only placebo, AEs were reported in The difference in frequency of AEs in the population who received active treatment was The difference was especially pronounced for neuropsychiatric events table 2. Most AEs were mild in intensity.
Sixty-four subjects in the atovaquone-proguanil group and 76 subjects in the mefloquine group discontinued use of the study drug prematurely. Begin daily for 3 days prior to travel, weekly during travel, and for 1 week after leaving.
One of the most effective drugs for prevention of P. Once a normal G6PD level is verified and documented, the test does not have to be repeated the next time tafenoquine is considered Cannot be used by children Cannot be used by pregnant women Cannot be used by women who are breastfeeding Not recommended in those with psychotic disorders.
To receive email updates about this page, enter your email address: Email Address. Malaria Notices. Malaria Hotline. Click here for contact information Contact Us. Links with this icon indicate that you are leaving the CDC website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. You will be subject to the destination website's privacy policy when you follow the link. CDC is not responsible for Section compliance accessibility on other federal or private website.
0コメント